You won't turn your nose up at Meda Pharmaceuticals' products, especially if you've got a runny one. The specialty drug firm makes a number of prescription remedies for allergies, including its flagship product, Astelin nasal spray antihistamine. Meda Pharmaceuticals also makes therapies in niche markets, such as central nervous system disorders (its Felbatol treats epilepsy), insomnia, muscle spasms, and women's health products. Its Onsolis is a transdermal version of cancer pain drug fentanyl that dissolves inside the patient's cheek. The company's sales force targets doctors and hospitals; it is the US subsidiary of Swedish drug firm Meda AB.
Meda Pharmaceuticals, also known as Meda USA, has research and development facilities near its headquarters in New Jersey; the company also operates manufacturing facilities in Illinois and New Jersey.
Meda Pharmaceuticals growth strategy includes continued product expansions through acquisitions, licensing deals, and internal development. In 2012 it acquired a small portfolio of products from Jazz Pharmaceuticals. The deal helped to build up Meda Pharmaceuticals' women's health line with such products as Elestrin, an estrogen replacement therapy.
The company re-worked Astelin into a new formula Dymista, that combines the azelastine antihistamine with fluticasone proprionate -- another commonly prescribed allergy nasal steroid spray. (Fluticasone is sold as a generic and under the brand name Flonase) Dymista received FDA approval in 2012 and the company hopes that it may become something of a blockbuster.
Meda Pharmaceuticals has to keep up a steady stream of new products as many of its drugs are faced with competition from generic products or other formulations. – less